In fact, its entire operation, like that of every other state-licensed marijuana supplier, remains illegal under the federal Controlled Substances Act.
It is therefore rather surprising that Yale researchers were allowed to use CTPharma's products—specifically, tablets containing plant-derived CBD and THC—in an FDA-approved Phase I clinical trial.
The study will be conducted at the Yale Stress Center, which is part of the university's medical school.
Ferrarese says he is not aware of any other FDA-approved study using marijuana produced in the United States that does not come from NIDA.
Update, January 15, 2020: The Yale/CTPharma study is now listed as a Phase I clinical trial at clinicaltrials.gov.